FY2024 EPS Estimates for Elutia Raised by Cantor Fitzgerald

Elutia Inc. (NASDAQ:ELUT) – Analysts at Cantor Fitzgerald boosted their FY2024 EPS estimates for Elutia in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will earn ($1.74) per share for the year, up from their previous forecast of ($1.76). Cantor Fitzgerald currently has a “Overweight” rating and a $10.00 target price on the stock. The consensus estimate for Elutia’s current full-year earnings is ($1.76) per share.

Elutia Stock Down 0.9 %

Shares of Elutia stock opened at $3.22 on Thursday. Elutia has a twelve month low of $2.28 and a twelve month high of $5.24. The company has a fifty day moving average price of $3.88 and a 200 day moving average price of $3.81.

Institutional Investors Weigh In On Elutia

Several institutional investors and hedge funds have recently modified their holdings of ELUT. Arcus Capital Partners LLC raised its holdings in shares of Elutia by 100.0% during the 3rd quarter. Arcus Capital Partners LLC now owns 20,000 shares of the company’s stock valued at $76,000 after buying an additional 10,000 shares during the period. Renaissance Technologies LLC raised its stake in shares of Elutia by 50.5% during the second quarter. Renaissance Technologies LLC now owns 53,616 shares of the company’s stock valued at $266,000 after purchasing an additional 18,000 shares during the period. Geode Capital Management LLC lifted its position in shares of Elutia by 50.3% during the third quarter. Geode Capital Management LLC now owns 188,408 shares of the company’s stock worth $718,000 after purchasing an additional 63,047 shares in the last quarter. Perkins Capital Management Inc. boosted its stake in shares of Elutia by 9.8% in the third quarter. Perkins Capital Management Inc. now owns 856,552 shares of the company’s stock valued at $3,263,000 after purchasing an additional 76,450 shares during the period. Finally, Nantahala Capital Management LLC boosted its stake in shares of Elutia by 8.8% in the second quarter. Nantahala Capital Management LLC now owns 1,795,697 shares of the company’s stock valued at $8,907,000 after purchasing an additional 145,697 shares during the period. Hedge funds and other institutional investors own 74.03% of the company’s stock.

Elutia Company Profile

Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.